Regenacy Pharmaceuticals

Regenacy Pharmaceuticals is a privately held company located in Waltham, Massachusetts. Founded in December 2016, the company employs six people and has generated $2.5 million in revenue. Regenacy Pharmaceuticals is focused on developing a novel treatment for peripheral neuropathies. Their lead compound, ricolinostat (ACY-1215), is an oral, selective inhibitor of the microtubule modifying enzyme HDAC6. The company is investigating ricolinostat for diabetic, chemotherapy-induced, and inherited peripheral neuropathies. Regenacy's approach aims to go beyond pain and symptom management by seeking to restore peripheral nerve function. Their research is based on preclinical studies that demonstrate the potential for ricolinostat to restore normal nerve function. In addition to ricolinostat, Regenacy has a portfolio of selective HDAC1,2 inhibitors with potential applications in cancer, hemoglobinopathies, and cognitive dysfunction. For more information about Regenacy Pharmaceuticals and their research, visit their website at regenacy.com.